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Abstract
One and a half million new cancer cases are reported each year in the United
States. Despite this overwhelming burden of disease, current preventative treatments and
early detection techniques are inadequate. With cancers, as with many aggressive
diseases, time is of the essence; earlier detection begets better patient prognoses. While
contemporary technology offers physicians the ability to battle cancers via stage-one
detection, few reliable biomarkers have been developed to assist in detection of upstream
tumorigenesis or interpretation of early genomic assault. The objective of the work
described here is to identify early biomarkers specific to tumorigenesis, which correlate
with initial genomic assault and subsequent mutation in the gpt-delta (B6C3F1) mouse
model. The test compound used in this work is aflatoxin B1, a known human carcinogen
produced by fungal spoilage of food materials. Aflatoxin B1 was one of the carcinogens
used in the "training set" of compounds that defined the B6C3F1 animal model. My work
had three goals with regard to upgrading this model as a tool for contemporary
toxicology. In the first part of the thesis, a kinetic profile was generated of AFB 1-DNA
adduct formation and removal. In the second part of the work, adduct levels and specific
DNA damage patterns of males and females were compared (males are generally more
sensitive than females to this and other toxins). Third, nursing mother mice were treated
with two chemo-preventive agents in an attempt to determine if chemoprevention of the
dam would lead to protection of her children.
This thesis documents generation of a 48-hour time-course assessing adduct-
burden in four-day-old B6C3F1 neonates. These burdens are measured in adducts per
mega-base of genomic DNA (based on a single 6mg/kg dose of AFB1). As previous
studies show that 6mg/kg at this age results in near 100% liver tumorigenesis, this time-
course provides significant intuition for the onset and persistence of DNA damage. The
results showed that AFB1-N7-Guanine adduct formation maximized at two hours post
dosing and then decreased rapidly; its FAPY derivative proved to be much more stable
with time. A slight excess adduct burden was observed in males from 2-48 hours post
dosing. Systematic differences in gene expression were observed in nursing female
mother mice that were either treated or not with R,S-sulforaphane or D3T (3H-1,2-
dithiole-3-thione). While minimal gene expression changes were observed in pups nursed
by a 2mg R,S-sulforaphane treated dam, those nursing from a 5mg R,S-sulforaphane
treated mother experienced much greater effects. At 300 umol/kg doses of D3T to the
mother, no statistically significant gene expression profile alterations were observed in
the pups. The work described here did not identify conditions in which a chemo-
preventive pattern of gene expression in the mother could be transferred efficiently to her
offspring.
Thesis Supervisor: John Essigmann
Title: Professor of Chemistry and Biological Engineering
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Introduction Chapter I
Aflatoxin B1 (AFB1) is a member of a larger class of mycotoxins produced by
species of the fungal genus Aspergillus, most notably Aspergillusflavus and Aspergillus
parasiticus. Since their discovery, aflatoxins have been at the center of academic inquiry,
known for their potency as toxins and carcinogens and their ubiquity in our world. Over
the past half-century a considerable amount of work has been done and literature
published on the subject of aflatoxin, from its biosynthesis to its mechanisms of action.
For this reason, aflatoxin B1 was used as the principal toxin to validate a new mouse
model, one which will provide valuable insight into the development of somatic cancers
and help to define future biomarkers capable of early disease detection.
My thesis research involved three contributions: (1) synthesis of '4C-AFB1 and
the AFBi-8,9-epoxide, for use in biochemical studies involving cells and the gpt-delta
mouse model; (2) adaptation of adduct measurement technologies to the AFB1/gpt-delta
mouse model system; (3) preliminary evaluation of the B6C3F1 mouse model as a tool
with which to identify and perform sensitivity analyses on agents that suppress adduct
formation and downstream cancer risk.
The remainder of the current chapter is devoted to providing a background on
aflatoxin-its history, chemistry, and mutagenic capacity-in addition to a new
transgenic mouse model used throughout this study: the gpt-delta B6C3F1 mouse. The
rest of this dissertation is organized as follows. Chapter II contains a detailed description
of the materials and methodology used for this study. Chapter III presents the results of
the various experiments that were conducted. Finally, Chapter IV summaries the
inferences that could be drawn from the experimental data on the synthesis of 14C-AFBi
and the AFBi-8,9-epoxide, the kinetics of AFBi adduct formation, and preliminary data
gathered on the use of chemopreventative agents to protect nursing pups from subsequent
AFB1 exposure.
Aflatoxin B1 : A Brief History.
Aflatoxins first made headlines in 1960 following a lethal enzootic outbreak in
England's southern and eastern captive poultry populations. The syndrome, dubbed
Turkey X disease, was known to cause extensive hepatic necrosis, hemorrhaging, and
frequent engorgement of the kidneys. Coincidental outbreaks in Uganda and Kenya's
duckling populations, as well as hatchery-reared rainbow trout in several regions of the
United State, helped researchers to link the illnesses to the animal feeds being used. From
that point researchers were able to identify the etiology of the disease as due to the
presence of a fungus, Aspergillusflavus, and eventually on a toxin, soon coined
aflatoxin-in light of its biological source.'
Following extensive work, both abroad and in the United States, four major
homologs of aflatoxin-AFB1, AFB 2, AFG1, and AFG 2-were structurally identified.2 7
It was soon shown that AFB1 -and to a lesser extent AFGi-were responsible for the
observed animal toxicity.'
It became evident that the problems affecting the animal feed and the downstream
consequence of liver damage were of broader concern: AFB1 might be responsible for the
high rate of hepatocellular carcinoma (HCC) in regions of Southeast Asia and sub-
Saharan Africa, where the presence of A. flavus was established and food production and
storage techniques were favorable for toxin formation."'8 Subsequent epidemiological
studies discovered an association between the ingestion of mold-contaminated foods
(predominantly corn, rice, and peanuts) and liver cancer, especially in populations co-
exposed to the hepatitis B virus-a still-inexplicable synergistic effect.
AFB1-DNA Adduct Formation.
A series of mechanistic studies were undertaken to determine method of action of
AFB1. It was hypothesized that the critical event in AFB1 activation was metabolism of
the 8,9-vinylic bond to the corresponding 8,9-epoxide. In vitro experiments, conducted
by Essigmann et al. demonstrated that the AFB1-exo-8,9-epoxide reacts with DNA to
form the 8,9-dihydro-8-(N7-guanyl)-9-hydroxyaflatoxin B, (AFBi-N7-Guanine) as the
primary adduct.9 (See Diagram 1) Several in vitro approaches demonstrated the ability of
AFB1 to intercalate double-stranded DNA.' 0 '1' This evidence, in support of previous
theory, suggested that pre-covalent association, between AFB1 and the base to which it
eventually becomes covalently bonded, is favorable for subsequent adduct formation.' 2
In vivo studies ensued; Cytochrome P450s were identified for their role in AFB1
activation, principally Cyp2cl 1 and 3a2 in ratsl3, Cypla2, 2a5, and 3a1 1 in mice'4 "5 , and
CyP3a4 in humans' 6"17. Additional in vivo experiments demonstrated the presence of
endogenous enzymes-glutathione transferases and epoxide hydrolases-which could
not only protect against the formed AFBI-8,9-epoxide but were found to be inducible by
both naturally occurring and synthetic compounds.'16'
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AFB1 Induced Mutagenesis.
Formation of the AFB1-N7-Gua adduct is known to lead to the formation of two
other major types of damage. The positively charged imidazole ring promotes either
depurination, giving rise to an apurinic (AP) site, or hydrolysis of the C8-C9 bond, to
form the biologically stable AFB1 formamidopyrimidine (AFB1-FAPY) DNA lesion.
From the genetic perspective, it has been postulated that these DNA adducts, or
downstream DNA damage, are responsible for the heritable changes that steer cells down
a path toward malignancy. Despite the structurally varied pool of DNA lesions formed in
cells treated with AFB 1, the mutational spectrum of the toxin across numerous systems is
dominated by a single genetic modification: a GC->TA transversion. 12 While it has been
suggested that the AFB1 induced AP lesion is responsible for the observed GC to TA
transversions1 8' 19, the parent AFB 1-N7-Gua adduct or FAPY lesion could theoretically
give rise to this mutation. Evidence has been presented that FAPY-major is the most
potently toxic DNA lesion and FAPY-minor is the principal mutagenic adduct of AFB1. 12
In addition to the capacity of AFB1 to cause point mutations, its ability to
intercalate DNA has been offered as an explanation for the ability of the toxin to induce
infrequent frameshift mutations.20
Chemo-Preventive Agents.
A variety of small thiol-active compounds, discovered initially in cruciferous
vegetables such as broccoli, cauliflower, and brussel sprouts, have been investigated for
years for their chemo-preventive capacity to fight cancer.2 1 Since their discovery,
compounds of both natural (i.e., R-sulforaphane and 3H-1,2-dithiole-3-thione (D3T))22
and synthetic (i.e., Oltipraz) origins have been exploited for their abilities not only to
induce Phase II enzymes (through activation of Nrf2-Keap1 mediated gene
transcription)23 24 but also to reduce select Phase I xenobiotic metabolizing Cytochrome
P450s. 2 5 These qualities have placed these compounds at the forefront of the fight against
AFB 1, effectively curtailing damages suffered at the hands of the toxin by bolstering the
body's abilities to intercept the electrophilic intermediates and minimize initial activation
to the 8,9-epoxide.
An Animal Model Fit For The Computer Age.
Over the years, animal models have been used to gain significant insight into the
human condition. Heightened environmental awareness in the 1960s and 1970s was met
by the development of a frontline testing approach, in which animal models served as
scientific tools to learn from and ultimately protect the public. Rats and mice became the
principal animal models for these studies. While preliminary experiments showed adult
mice to be resistant to a variety of genotoxic chemicals, subsequent work depicted
differences in the animal's toxic and mutagenic susceptibility as a function of both strain
and age at time of exposure. The B6C3F1 (the F1 from mating C57BL/6J female and
C3H male mice) mouse strain, in particular, was highlighted in a series of experiments
for its heightened mutagenic susceptibility during the first 4 to 14 days of life and
increased resistance thereafter. Mice exposed to various carcinogens, specifically AFB1 ,
during this window of susceptibility had a 100% tumor incidence, while those treated
outside the susceptibility window had minimal signs of tumorigenesis.1 Forty years later
the wherewithal now exists to "upgrade" the original B6C3F1 model to provide even
greater scientific functionality. This so-called model modernization involved the insertion
of several recoverable phage shuttle vectors with a gpt reporter gene, which enable
genetic alterations to be detected earlier in the development of somatic diseases-in this
case, liver cancer.
Materials and Methodology Chapter II
Chemicals
Aflatoxin B1 (AFB1), calcium chloride (CaCl2), cremophor EL, cupric sulfate (CuSO 4),
dichloromethane anhydrous (CH 2Cl 2, anhydrous), d6-dimethyl sulfoxide anhydrous (d6-DMSO,
anhydrous), dimethyl sulfoxide (DMSO; biotechnology performance certified grade), disodium
ethylene diamine tetraacetate solution (0.5M Na2EDTA; molecular biology grade), ethylene
diamine tetraacetic acid (EDTA), ferrous sulfate (FeSO4), Glutathione-S-Transferase (GST)
Assay Kit, 8-hydroxyquinioline, lysozyme (lyophilized powder from white chicken eggs),
manganese sulfate (MnSO 4), 3[N-morpholino] propanesulfonic acid (MOPS),
phenol:chloroform:isoamyl alcohol (25:24:1 saturated with 10 mM Tris, pH 8.0, 1 mM EDTA),
potassium peroxymonopersulfate (Oxone@, monopersulfate), Proteinase K (lyophilized powder
from Tritirachium album, biological grade), sodium borate (Na 2B40 7), sodium acetate
(NaCH3CO 2), sodium dodecyl sulfate (SDS), sodium molybdate (NaMoO4), triton x-100, zinc
sulfate (ZnSO 4) were obtained from Sigma Chemical (St. Louis, Misouri). Acetone ((CH 3)2 CO,
HPLC reagent grade), acetonitrile (CH 3CN), ammonium sulfate ((NH 4)2 SO 4), chloroform
(CHC13), acetone ((CH 3)2CO), methanol (MeOH), dichloromethae (CH 2 Cl2), D-glucose, ethanol
(EtOH), ferric chloride (FeCl3 ), ferrous sulfate (FeSO4 ), hydrochloric acid (HCL, 13N),
magnesium sulfate (MgSO 4), potassium phosphate mono basic (KH2PO4), sodium bicarbonate
(NaHCO2), sodium hydroxide, sodium chloride, sodium citrate, sodium phosphate dibasic
(Na2HPO 4), tris base were obtained from Mallinckrodt Baker (Phillipsburg, New Jersey).
DifcoTM potato dextrose agar (PBA) and Luria-Bertani lysogeny broth (LB) were obtained from
Becton, Dickinson and Company (Franklin Lakes, New Jersey). 14 C- 1-Sodium acetate
(CH3[14C]O 2Na, 59.2mCi/mmol) was obtained from Moravek Biochemicals (Brea, California).
15N-Ammonium chloride ('5NH4Cl) was obtained from Cambridge Isotope Laboratories
(Cambridge, Massachusetts). QIAshredder tissue lysate homogenizer kit, QuantiFast SYBR
Green RT-PCR Kit, RNase A solution (100 mg/mL, 7000 units/mL), RNeasy Mini Elute
Cleanup Kit, RNeasy Protect Mini Kit were obtained from QIAGEN (Valencia, California).
DNA primers for real time RT-PCR were ordered from Integrated DNA Technologies
(Coralville, Iowa). 3H-1,2-dithiole-3-thione (D3T) and (R,S)-sulforaphane was obtained from
LKT Laboratories (St. Paul, Minnesota). GibcoTM Dubelcco's phosphate-buffered saline (lx)
solution (DPBS) was obtained from Invitrogen (Carlsbad, California). Braadford reagent was
obtained from Bio-Rad Laboratories (Hercules, California). Miracloth was obtained from EMD
Chemicals (San Diego, California).
*Unless otherwise specified, chemicals were used in their hydrated forms.
Biologicals
Aspergillusflavus was obtained from Greg O'Brian (Payne Laboratory, North Carolina
State University). Time-pregnant C57BL/6J females mice (mated with C3H males) were
obtained from Jackson Laboratories (Bar Harbor, Maine). gpt-delta C57BL/6J mice were
provided by Dr. T. Nohmi (Tokyo, Japan). Upon arrival, all mice were switched over to an
ethoxyquin-free (supplied by TestDiet, Richmond, Indiana) diet to avoid artificial elevation of
basal antioxidant levels. Mice were feed ad libitum.
HPLC Parameters
For all HPLC runs described below, an identical HPLC solvent system and method was
used.
Sodium acetate (50mM), 10% acetonitrile aqueous and 100% methanol organic mobile
phase solvents were prepared and vacuum filtered over 0.20pm, 47mm, nylon Phenex filter
membranes prior to use. HPLC analysis of aflatoxin B1 and its derivatives was accomplished
utilizing a 20min flow gradient, with a 5min hold at 100% organic, and an 8min reverse gradient
on a C18 column with a flow-rate of lmL/min. A UV/Vis-diode array spectrophotometer and a
serialized scintillation flow-analyzer were used both independently and in concert to obtain data
and ultimately generate spectra.
14C-Aflatoxin B1 Synthesis
Fungal species Aspergillusfavus (NRRL 3357) was used in the synthesis of 14C-
aflatoxin B1. A. flavus was grown on solid phase DifcoTM potato dextrose agar (PDA) plates at
28*C and stored on PDA slants at 4'C.
A. flavus conidia were isolated from confluent P-100 PDA plates using 5-15mL
autoclaved 0.05% (by volume) Triton X-100 solution. Conidial release was facilitated by gentle
mechanical disruption using a sterilized glass spreader. The resulting conidia suspension was
collected and the conidia counted using a double levy hemocytometer (1/1000x dilution).
Shaken suspensions were prepared by adding 1.5g D-glucose, 150mg ammonium sulfate,
500mg potassium phosphate mono basic, and 100mg magnesium sulfate to 50mL H2 0, filtering
over a Nalgene 0.20ptm cellulose acetate vacuum filter system, and combining with 50pIL 1000x
metal mix (70mg sodium borate, 68mg sodium molybdate, 1.Og ferrous sulfate, 30mg cupric
sulfate, 176ig zinc(II) sulfate, and 11mg manganese(II) sulfate in 1OOmL H20 filtered over a
Nalgene 0.20im cellulose acetate vacuum filter) in a 250mL baffled flask. 108 A. flavus conidia
(106 spores/mL) were inoculated into the 5OmL of media and shaken at 100rpm (switched to
200rpm after 24hr) at 28*C for 72hr. While still shaking, 1mCi 14C-i-acetate (lmCi/mL,
59.2mCi/mmol) was added in three installments over a period of 8hr and allowed to shake for an
additional 16hr at 28 0C.
Shaken cultures were filtered over a course glass frit through MiraCloth and washed with
30mL filtered H20. Three equal-volume chloroform extractions were performed on the filtrate in
a 500mL separation funnel and subsequently dried in a 500mL round-bottom flask using a rotary
evaporator. The dry crude extraction was dissolved with 1 OmL chloroform, transferred to a
50mL round bottom flask and dried once again. 1mL methanol was added to the dry crude
extract and 1 0pL were subsequently analyzed via a serialized HPLC-UV/Vis-scintillation
analyzer system. UV-Vis AFB1 peak was observed at 18.7min with a 14C-radioactivity trace
trailing closely. Total crude extract 14C-radioactivity was determined to be 138,000cpm by
analyzing a 10p L aliquot (of total 1mL) on a multipurpose scintillation counter.
The crude extract was purified using a 30mm flash-column chromatography setup and
resolved with an 85:15 chloroform:acetone mobile phase. 5-10mL fractions were collected and
evaluated for 14C-AFB1 activity using a multi-purpose scintillation counter. 14C-containing
fractions were combined into a 1 L round-bottom flask, concentrated via rotary evaporation, and
analyzed using HPLC.
AFB1 8,9-Epoxide Synthesis and Quantification
All glassware was washed with soap and H20, rinsed thoroughly with H20, dried with
acetone, and then oven-dried at 1 000C.
AFB 1-exo- and endo-8,9-epoxides were synthesized in an 8:1 ratio utilizing a
dimethyldioxirane (DMDO) synthetic approach. DMDO was synthesized via a vacuum
distillation procedure (obtained from William Kobertz's laboratory notebook). In a 200mL
round-bottom flask, equipped with stirbar, 6g sodium bicarbonate was combined with 1 OmL
filtered H20 and 1OmL reagent-grade acetone, and set to stir. Oxone (12.5g) was added, allowed
to mix for one minute, and then vacuum distilled for 30min at 60'C into a 50mL collection flask,
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cooled to -78*C in a dry ice/acetone bath. DMDO concentration was determined by obtaining a
UV absorbance at 335nm (6335, acetone = 10 M-cm-').
The AFBi-8,9-epoxide was synthesized by adding 5pmol DMDO drop-wise
(immediately following synthesis) to multiple stirring solutions of 1mg AFB1 (1.5x, by moles) in
200ptL anhydrous dichloromethane in silanized 1.5mL glass vials, equipped with mini-stirbars.
The vials were capped and the mixtures left to stir vigorously at room temperature for 20min.
The reaction mixtures were combined into a single vial and additional dichloromethane was used
to wash the voided vials. The solvent was then evaporated, via rotary evaporation for 30min, the
dried epoxide was sealed under argon using a threaded Teflon cap, and stored at -80*C.
In order to quantify the AFBi-epoxide, the stored material was dissolved in 700pL
anhydrous d6-DMSO and a UV absorption was obtained at 363nm against a DMSO background.
The AFB 1-8,9-epoxide concentration was approximated using the extinction coefficient for
AFB1 in methanol (6363,AFB1,MeOH,363= 2 2 ,000 M-1cm'). The AFBI-epoxide solution was pipetted
into a washed and dried glass NMR tube and a 1H-NMR (32 scans) was obtained. In addition,
IH-NMR (32 scans) spectra were generated for AFB1 and the AFB1-8,9-diol (by adding a few
drops of H20 to the AFBi-epoxide NMR tube and letting it sit for multiple days). The final
concentration of the exo-8,9-AFB 1-epoxide was estimated by determining the fraction of each
species present (AFB1, exo-AFB 1-8,9-epoxide, endo-AFBI-8,9-epoxide, and AFB1-8,9-diol),
based on integration values of unique hydrogen chemical shifts.
AFBr-DNA Standard Synthesis
Both light and heavy, "4N and "N-labeled, AFB 1-DNA standards were synthesized for
use in developing a Stable-Isotope Mass Spectrometry (SIMS; aka Tandem Isotope Dilution
Mass Spectrometry) system for AFB 1-DNA damage analysis at MIT.
15N-DNA Biosynthesis.
Escherichia coli (obtained from Dr. Robert Croy) was grown in a four-part minimal
media environment (lOx Complex-Salts solution: 1.5g magnesium sulfate, 2.5g sodium citrate,
3.75mg calcium chloride, 150mg disodium EDTA salt, 125mg ferric chloride, 1.25mg cupric
sulfate, 900pg manganese sulfate, 140ptg zinc sulfate, 1.35mg calcium chloride anhydrous in
500mL H20 filtered over a Nalgene 0.20ptm cellulose acetate vacuum filter; M9-Salts solution:
3g potassium phosphate mono basic, 6g sodium phosphate dibasic, 500pjg sodium chloride in 1L
H2 0 filtered over a Nalgene 0.20 jim cellulose acetate vacuum filter; 40% D-glucose solution:
20g D-glucose in 50mL H2 0 filtered over a Nalgene 0.20pm cellulose acetate vacuum filter;
15N-ammonium chloride solution: Ig 15N-ammonium chloride in 1OmL filtered H2 0). 713piL 1Ox
Complex-Salts, 7.13mL M9-Salts, 85.6jpL 40% D-glucose, and 71.3ptL 15N-ammonium chloride
solutions were combined, inoculated with a single . coli colony, selected from a previously
streaked antibiotic-free LB plate, and shaken upright at 200rpm for 24hr at 36-38'C. The 8mL
growing E. coli suspension was inoculated into a larger 500mL shaken culture (500mL M9-Salts,
50mL Complex-Salts, 6mL 40% D-glucose, 5mL 1.8M 15NH4 C1 solutions) in a 2L baffled flask
and left to shake at 250rpm at 38'C for an additional 24hr. The 500mL 15N-culture was spun
down at 10,000xg (8,000rpm on a GSA rotor) for 10min at 4'C. The resultant pellet was re-
suspended in 1 OmL 50mM TE buffer (pH 8), flash frozen, and stored at -80'C.
1 5N-DNA Isolation.
In order to isolate "N-DNA, 3mL 250mM Tris (pH 8) and 10mg lysozyme were added to
the 15mL frozen E. coli suspension. The mixture was allowed to thaw at room temperature and
then placed on ice for 45 minutes. 5mL 50mM Tris/400mM EDTA (pH 7.5), 2mL 5% SDS, and
10mg Proteinase K were added to the thawed mixture and then incubated at 50 C until
membranes and larger protein aggregates were fully dissolved. Equal-volume phenol/chloroform
washes were performed on the digested E. coli mixture and resolved by centrifugation at
10,000xg (9,200rpm on an SS-34 rotor) for 20min at room temperature. 0.1-volume 3M sodium
acetate was added to the aqueous phase and the solution was mix gently by inverting. Two-
volumes cold ethanol were added to precipitate the DNA and the DNA was subsequently spooled
on a glass rod. The collected DNA was washed with cold 70% ethanol and dried briefly under
vacuum. The spooled DNA was re-dissolved in 5mL 50mM Tris/lmM EDTA (pH 7.5) and
rocked at 4'C until fully dissolved. 5mg RNase A was added and the solution was rocked
overnight at 4'C. Equal-volume phenol/chloroform and chloroform washes were performed and
the DNA was precipitated by adding 0.1-volume 3M sodium acetate and two-volumes cold
ethanol. The precipitated DNA was spooled on a glass rod, washed with cold 70% ethanol, dried
briefly under vacuum, and re-dissolve in sterile H20. The final DNA concentration was
determined by UV-absorption at 260nm (1.OA = 50pg/mL double-stranded DNA). The dissolved
DNA solution was flash frozen and stored at -20*C.
AFB 1-15N-DNA Adduct Synthesis.
AFB 1-8,9-epoxide was synthesized by adding 5pmol DMDO drop-wise (immediately
following synthesis) to a stirring solution of 1mg AFB1 (1.5x, by moles) in 200pL
dichloromethane in a silanized 1.5mL glass vial, equipped with a mini-stirbar. The vial was
capped and the mixture was left to stir vigorously at room temperature for 20min.
To the stirring AFB1 solution, 2mg 15N-DNA in H20 (1.6mg/mL) were added and
allowed to stir for an additional 10min. The AFBI-DNA mixture was washed with an equal-
volume of phenol/chloroform, followed by an additional equal-volume wash with just
chloroform. The DNA was precipitated, by adding 0.1-volume 3M sodium acetate and two-
volumes cold ethanol, spooled on a glass rod, washed in cold 70% ethanol, and dried under
vacuum. The DNA was re-dissolved in either lmL H20 (to obtain the AFB 1-N7-Guanine adduct)
or 1mL 50mM TE buffer (pH 8.6) (to obtain the AFB1-FAPY adduct), sonicated, flash frozen,
and subsequently stored at -20'C for future hydrolysis.
Glycosidic acid-hydrolysis of AFB 1- N-DNA was accomplished by adjusting the thawed
DNA solution to 0. IN hydrochloric acid and subsequently incubating at 95'C for 1 0min. The
hydrolyzed solution was cooled on ice, neutralized using a 2N sodium hydroxide solution, and
adjusted to 10% methanol for subsequent purification. The hydrolyzed AFB 1-N7-Guanine (or
FAPY) adducts were purified using a Phenomenex reverse-phase C18-E Sephadex preparation
column and a 10/100% methanol wash/elution solvent system. Three 1mL eluted fractions were
collected, concentrated under argon, and further purified via HPLC. AFB 1-N7-Guanine peaks
were observed around 15.8min and eluted from the line at around 15.9min, while AFB1-FAPY
peaks were observed around 15.1min and eluted around 15.2min. A total of four AFB 1-15N7-
Guanine fractions and eight AFB1-15N-FAPY fractions were collected, combined separately, and
concentrated under argon. The purified standards were desalinated, for subsequent mass-
spectrometry analysis, using another C18 Sephadex column and a 10/100% reagent-grade
methanol wash/elution solvent system. Eluted fractions were concentrated under argon and
quantified via a UV/Vis spectrophotometer in methanol (AFB1-N7G,364,H2O = 16,100 M'cm').
Determined concentrations were approximate, as measurements were made in methanol instead
of H20. Due to lack of available literature, the CAFB1-FAPY was assumed to be identical to reported
SAFB1-N7G. Purified standards were ultimately stored at -20*C in methanol until needed.
AFB-DNA Adduct Studies
Aliquoting Aflatoxin B1.
(AFB1 aliquots were prepared via this method prior to use.)
2mL dichloromethane was added to a "5mg" vial of AFB1, gently inverted, and mixed until full
dissolved. Using a Hamilton glass syringe, 100 pL (approximately 250ptg) aliquots were placed
in 1.5mL silanized vials. Due to the volatility of dichloromethane, aliquots were made a fast as
possible, taking care to recap the stock in between each aliquot (typically, less than the expected
20 aliquots were made due to solvent evaporation). Once completely aliquoted, the contents of
each vial were dried under argon and capped (the order in which the vials were aliquoted was
maintained throughout). Three to four aliquots-from the beginning, middle, and end-were
sacrificed, dissolved in methanol, and quantified via UV absorption (6363,MeOH = 22,000 M 1cm 1 )
to generate a polynomial regression capable of approximating final AFB1 amounts in the
remaining vials. Vials were labeled accordingly and stored at 4'C.
Dosing Four-day-old Pups.
Four-day-old pups (both male and female) were treated with a 6mg/kg dose of AFB1 in
1 0tL dimethylsulfoxide (DMSO) via IP injection. Pups were placed back with their mothers and
euthanized by CO2 at 2, 4, 8, 12, 24, and 48hr after dosing. At the time of killing, each pup's
liver was taken, flash-frozen on dry ice, and stored at -80*C for future DNA isolation-each
pup's gender was recorded for future analysis.
Liver DNA Isolation.
The following steps, up to the addition of SDS, should be performed with ice-cold
solutions-preferably in a cold (40C) room.
Frozen liver samples were removed from -80'C, cut into small pieces, and suspend in
nine-volumes (lmL/g) of ice-cold sucrose buffer (250mM sucrose, 2mM calcium chloride,
10mM MOPS, pH 7). The suspension was placed in a 10-20mL Dounce homogenizer, and
homogenized using both "A" and "B" pestles (approximately 10 strokes with "B"). While
stirring, an additional volume of ice-cold sucrose buffer solution--containing 25% Triton X-100
(by volume)-was added, the solution was transferred to a centrifuge tube, and centrifuged at
1 000xg for 1 0min at 4"C. The supernatant was discarded, and the white pellet of liver cell nuclei
was suspended in 5mL ice-cold TNE buffer (50mM MOPS, 10mM EDTA, 100mM sodium
chloride, pH7) containing 0.5mg/mL Proteinase K. Seven hundred pLL room-temperature 5%
sodium dodecyl sulfate (SDS) in TNE was added and the tube was rocked (the solution was
never vortexed nor mix by pipette), ensuring sufficient mixing of the SDS and complete lysis of
the nuclei, and then incubated for 1hr at 370C (in the event that visible clumps of material were
present after lhr, more 5% SDS solution was added and mixed by inversion until a clear solution
was obtained).
Following incubation, an equal-volume phenol/chloroform solution (pH 7) was added
and inverted gently, creating a white emulsion. The emulsion was resolved by centrifugation at
10,000rpm for 1 0min at room temperature. The upper aqueous phase was carefully collected, an
equal-volume of chloroform added, and mixed well by inversion. The mixture was centrifuged
again at 10,000rpm for 10min at room temperature. The aqueous phase was carefully collected
and transferred to a new tube on ice. A 0.1 -volume 5M sodium chloride solution was added, the
solution was mixed well by inversion, centrifuged briefly, and then placed on ice once again.
DNA was precipitated by adding three-volumes cold (-20'C) ethanol and subsequently mixed by
inversion. The DNA was pelletted by centrifugation at 10,000rpm for 1 0min at 4'C, the
supernatant was gently decanted off, and the DNA pellet collected. To wash the DNA pellet,
4mL cold 70% ethanol was added and the DNA was re-suspended by flicking the tube. The
DNA was centrifuged once again at 10,000rpm for 1 0min at 4"C and the ethanol wash was
carefully decanted off. To evaporate residual ethanol the tube was propped open for 15-20min.
To removal residual RNA, the DNA was fully dissolved in 4mL TE buffer (pH 7), RNase
A was added (for a final concentration of 4ptg/mL), and the solution was incubated for 30min at
37'C. The incubated solution was washed, first with an equal-volume phenol/chloroform
solution and then with chloroform, as described above. A 0.1-volume 5M sodium chloride
solution was added to the recovered aqueous phase, mixed well and precipitated with ice-cold
ethanol, as described above. The DNA was pelletted, via centrifugation, washed with 70% ice-
cold ethanol and then dried at room temperature, as prior. The DNA was re-dissolved in H20,
flash-frozen on dry ice, and subsequently stored at -800C.
Stable Isotope Mass Spectrometry (SIMS) AFB1-DNA analysis.
Isolated DNA (50-100ptg) was spiked with 5pmol of both AFB 1- 5N7-Gua and AFB 1-
isN-FAPY, the solution was adjusted to 0.1N hydrochloric acid, and incubated at 95'C for 10min
to hydrolyze the glycosidic bond. The solution was neutralized with sodium hydroxide and then
adjusted to 10% methanol. AFB 1-DNA adducts were collected on a 10% methanol primed self-
made mini-scale C18 sephadex column, washed with 100 ptL 10% methanol, and eluted with
150ptL reagent-grade methanol.
Reverse phase HPLC-SIMS analysis of acid-hydrolyzed AFB 1-DNA adducts was
accomplished using a 20min (0.25% acetic acid aqueous/0.25% acetic acid methanol) flow
gradient, with a 5min hold at 100% organic, and an 8min reverse gradient on an ACE C18
column with a 10 pL/min flow-rate. A triple-quadrapole mass analyzer was used to quantify
AFB 1-N7-Gua and AFB 1- 5N7-Gua levels by first selecting for parent ions 480.1000 and
485.1000M/Z and then measuring product ion abundance at 152.0996 and 157.0996M/Z,
respectively; AFB1-FAPY and AFB 1-15N-FAPY levels were quantified by first selecting for
parent ions 498.1000 and 503.1000M/Z and then by measuring product ion abundance at
452.1016 and 457.1016M/Z, respectively.
AFB 1-DNA adduct formation was ultimately calculated by relating the '4N/' 5N product
ion ratios back to the initial 5pmol additions of the 15N-internal standards.
Chemo-Preventive Intervention
Aliquoting Sulforaphane.
R,S-Sulforaphane (MW: 177.29, golden viscous liquid) was aliquoted in 5mg or 8mg
quantities in preparation for 2mg or 5mg dosages, respectively. R,S-Sulforaphane (100mg) was
dissolved in 1mL reagent-grade methanol, quantified via a UV/Vis spectrophotometer at 238nm
(6238,H2O = 910 M1cm 1), and aliquoted accordingly into 1.5mL Eppendorff snap-top tubes. The
vials were placed on a rotary speed vacuum apparatus and their contents evaporated for 25
minutes. Two randomly selected aliquots were sacrificed and quantified to assess the final
amount of sulforaphane present. The remaining aliquots were stored at -80'C for future use.
Aliquoting 3H-1,2-dithiole-3-thione (D3T).
D3T (MW: 134.25, brownish-red solid) was weighed out on a milligram scale.
Dosing Regimen.
Nursing mother mice were gavaged on days four, five, and six post-partum with either
2mg or 5mg R,S-sulforaphane, 300pmol/kg D3T, or vehicle control. Nursing moms and their
respective litters were euthanized under CO 2 eight hours following the day six dosing, their
livers collected, flash frozen over pulverized dry ice, and stored at -80*C for future RNA and
protein isolation.
For sulforaphane dosing, a single R,S-sulforaphane aliquot was removed from -80'C and
suspended in sufficient corn oil to yield a 51.4 (2mg) or 141mM (5mg) suspension. 200pLL of the
R,S-sulforaphane suspension was measured out, the gavage needle was preloaded with the
remaining suspension, and the entire dose was delivered to the nursing mom.
D3T aliquots were prepared afresh for each mouse-dosing event. A 45mM stock D3T
solution was prepared based on calculations for a 300pmol/kg dose, a 30g four-day post-partum
female mouse, and a maximum gavage volume of 200pL. Weighed D3T was dissolved in a
DMSO:Cremophor:DPBS vehicle in a 1:1:8 ratio. Nursing moms were weighed prior to each
gavage, the gavage needle (100-150ptL dead-volume) was preloaded with the D3T suspension,
and the appropriate amount of D3T was delivered to each animal (no additional vehicle was
added to adjust the final dose volume).
Glutathione S-Transferase (GST) Activity Assay.
Frozen liver samples for both the six-day-old pups and nursing moms were removed from
-800C, 20-30mg sections were measured out, and homogenized, via a Dounce homogenizer, in a
250mM sucrose solution (1OmL/g). The homogenate was centrifuged (using Beckman TL-100
ultracentrifuge) for 1hr at 45,000rpm (105,000xg) at 40C. The supernatant (cytosolic fraction)
was diluted 1/1000x and assayed for GST activity using a GST Assay Kit (Sigma Aldrich,
Catalog#: CSO410). A 20mL master-mix containing only the Dulbeco Phosphate Buffer and
200mM reduced L-glutathione was prepared (the chlorodinitrobenzene (CDNB) substrate was
left out to avoid non-enzymatic nucleophilic aromatic substitution). CDNB (9.9ptL) was added to
980.1 pL L-glutathione master-mix, the solution was mixed well, and used to blank the UV/Vis
spectrophotometer at 340nm. 10iL diluted 105,000g-supernatant (1/1000x) was added to the
blanking solution, inverted for 1min, and A340 was recorded for 5min in 30sec intervals. A
positive control, supplied in the kit, was assessed for reproducibility after every four samples.
GST-assayed solutions were recovered following kinetics measurements, diluted 4/5x with 5x
Bradford Reagent, and assayed at 595nm to determine the total protein concentration for each
sample. Liver cytosol GST activities were reported as normalized values in mmol/min/mg total
protein.
RNA Isolation.
Frozen liver samples for both the six-day-old pups and nursing moms were removed from
-800C, 15-30mg sections were measured out and kept frozen on dry ice. The aliquoted tissue
samples were submerged in liquid nitrogen and mechanically disrupted via mortar and pestle.
Tissue lysate was subsequently homogenized using a QIAGEN QlAshredder microcentrifuge
spin-column homogenizer. Hepata-cellular RNA (larger than 200 nucleotides) was isolated from
each sample using the QIAGEN RNeasy Mini Kit with a final elution volume of 1 00ptL. Each
RNA isolate was concentrated and further purified for future RT-PCR application using the
QIAGEN RNeasy MinElute Cleanup Kit. Final isolated RNA concentration was determined for
each sample via UV absorbance at 260nm (A260 = 1 = 44ig/mL RNA, pH 7).
One-Step Real-Time RT-PCR.
One-step real-time RT-PCR was performed on hepata-cellular RNA isolates from 2 and
5mg R,S-sulforaphane, 300[pmol/kg D3T, and vehicle-control treated nursing mother mice and
their respective nursing litters. Real-time RT-PCR was performed on a Roche LightCycler 480
system utilizing the QIAGEN QuantiFast SYBR Green RT-PCR Kit. DNA primer-sets (both
forward and reverse primers) were designed and tested for genes involved in AFB1 and other
Phase I metabolism (Cypla2, Cyp2a4/5, Cyp2b9, and Cyp3a 11), Phase II metabolism (Gsta2,
Gsta3, Gclc, and Ephx 1), Nrf2 response (Nqo 1), and cellular housekeeping functions (Aip and
Cxxc 1). RT-PCR reactions were prepared in clear 96-well plates on ice to avoid premature
reverse-transcription. A single negative-control and four geometric standards (1, 0.1, 0.01, 0.001)
were run for each primer-set, in addition to those samples of interest. Each reaction-well
contained a final reaction volume of 25ptL: 12.5ptL 2x SYBR Green mix, 0.25tL QuantiFast RT
mix, 5.25pL RNase-free H20, 2pL 12.5ptM DNA primer-set solution, 5pL 20pg/mL isolated
RNA template. Following logarithmic regression analysis on each of the geometric standard sets,
RNA levels were reported for each monitored gene relative to the average of the two
housekeeper genes (Aip and Cxxc 1). The Student T-Test was used to detect statistically
significant differences between treatment and control groups.
Results Chapter III
This thesis had three primary objectives. In the first, permissible growth and 14C-labeling
conditions were determined for AFB1 biosynthesis utilizing the fungus Aspergillusfavus.
Synthesis and quantification/characterization of the AFBi-8,9-epoxide (via NMR) was
accomplished and the product of that synthesis was employed in the preparation of AFB1-
(14N,"N)-DNA adduct standards. The second objective was to measure the kinetics of AFB1-
DNA adduct formation and elimination in four-day old male and female mice. The third, and
final, objective was a preliminary investigation into the consequences of chemo-preventive
agents on the gene expression and GST-enzyme activity of nursing mothers and their feeding
pups.
4C-Aflatoxin B1 Synthesis
Optimal growth conditions and permissible 14C-labeling requirements were determined
following an iterative approach. A 72hr label-free growth period and a subsequent 24hr labeling
interval produced a total of 6.5uCi crude 14C-labeled AFB1 from 1mCi sodium 14C-I-acetate
salt-a synthetic incorporation of 0.65%.
Aflatoxin B1-8,9-Epoxide Synthesis and Quantification
The first step in the formation of the AFBi-8,9-epoxide was production of
dimethyldioxirane (DMDO). Concentrations of synthesized DMDO in acetone fell between 70
and 97mM. Subsequent reaction of DMDO with AFB1 resulted in nearly complete oxidation of
AFB1 to the desired 8,9-epoxides. Characterization of the AFBI-8,9-epoxide reaction mixture,
via 'H-NMR (see Figure 2), depicted the presence of three distinct aflatoxin species, AFB1-exo-
8,9-epoxide, AFB1-endo-8,9-epoxide, and unreacted AFB 1, in a ratio of 21:3:1 (determined from
the ratio of integration values for proton chemical shifts at (H9a, AFB1-exo-8,9-epoxide) 4.57,
(H9a, AFB1-endo-8,9-epoxide) 4.28, and (H8, AFB1) 6.75ppm). UV absorbance of the aflatoxin
coumarin backbone (at 363nm) in d6-DMSO (using the extinction coefficient of AFB1 at 363nm
in methanol) was consistent with a total aflatoxin concentration of 13.9mM. Assuming all
species absorbed equally at 363nm, the final concentration of AFB 1-exo-8,9-epoxide was
calculate to be 11.67mM.
Aflatoxin B1-DNA Standard Synthesis
"N-DNA was synthesized using an E. coli suspension culture. Following a 48hr growth
period, 1 OmL of 1.67mg/mL 15N-DNA was obtained. AFB 1-DNA adduct standards were
subsequently synthesized (via successful reaction with the AFB1-8,9-epoxide mixture), purified,
and desalted yielding 1mL methanol solutions for each of the four standards: 25.8pLM AFB 1-
15N7-Gua, 30.6ptM AFB1-'4N7-Gua, 31.8ptM AFB1 -"N-FAPY, and 21.3pjM AFB 1 -14N-FAPY.
Aflatoxin B1-DNA Adduct Studies
Four-day old pups were dosed with 6mg/kg AFB1 via IP injection. Pups were killed,
livers collected, and whole-liver DNA isolation was performed (by Dr. Leslie Woo) on B6C3F1
mice birthed from C57BL/6J pregnant mothers purchased from Jackson Labs. DNA was isolated
for at least three male and three female B6C3F 1 pups for each of the six time-points of interest
(2, 4, 8, 12, 24, 48hr post-dose). Isolated DNA for the B6C3F1 mice were analyzed for AFB 1-
DNA (only AFB1-N7-Gua) adducts (by Patricia Egner at Johns Hopkins University) via Stable
Isotope Mass Spectrometry (SIMS) using the synthesized 15N-standards. Results depicted AFB1-
N7-Gua adduct peaks for both males and females at 2hr at an average of 8.35 and 9.46
adducts/MB, respectively. (See Figure 5) AFB 1-N7-Gua adduct levels decreased significantly
over the next 46hr. Based on preliminary experiments, AFB1-FAPY adduct levels peaked at 2hr
(5.9 adducts/MB), decreased at 4hr, peaked again at 8hr (5.7 adducts/MB), and then decreased to
about 4 adducts/MB by 48hr (see Figure 6).
Chemopreventative Intervention
Six mothers were successfully gavaged with either 2 or 5mg R,S-sulforaphane,
300pmol/kg D3T, or the respective vehicle controls and were healthy and willing enough to
nurse their pups for three consecutive days (days four to six post-partum). A successful course of
treatment was gauged by minimal weight-loss from the treated mother (<2g loss) and steady
daily weight-gain from the nursing pups (>1.5-2mg gain/day). All six-day pup livers were
collected from each litter and the two mothers treated with either D3T or vehicle control. Ideally,
liver samples from three litters for each the control and D3T-treated groups would have been
collected, but unforeseen issues of D3T toxicity were encountered resulting in neglected
newborns and even dead mothers. Attempted AFB 1-DNA adduct studies following pre-treatment
with D3T, while attempted, were unsuccessful as well due to similarly observed D3T toxicities.
RNA was successfully isolated from partial livers aliquots (15-30mg sections) for 31 of
the collected mouse livers: four pups nursing from both the 2mg R,S-sulforaphane and respective
vehicle control-treated mothers, six pups nursing from both the 5mg R,S-sulforaphane and
respective vehicle control-treated mothers, four pups nursing from the 300pmol/kg D3T-treated
mother and five pups nursing from the respective vehicle control-treated mother, and the two
mothers treated with either D3T or vehicle control. Isolated RNA was further purified and
concentrated down to 12uL RNA solutions with concentrations varying between 2.5 and
4.5mg/mL.
RT-PCR data was successfully collected for each of the isolated RNA samples and
normalized by the average of two treatment-independent housekeeping genes. Relative mRNA
levels, fold-change ratios between treatment and control groups, and p-values for each of the
interrogated genes are reported in Table 3. Individual data for each analyzed mouse in addition to
group averages are further depicted in Figures 7-15.
Partial liver cytosolic fractions (105,000xg) were obtained and assayed for GST-activity
for 19 mice in total: one pup from both the 5mg R,S-sulforaphane and the respective vehicle
control exposed litters, seven pups from the D3T exposed litter, eight from the D3T vehicle
control litter, and the two mothers treated with either D3T or vehicle control. No detectable
differences were observed between the two 5mg R,S-sulforaphane treatment and control pups,
nor the 300pmol/kg D3T treatment and control groups (when a GST over-induced control pup
outlier was corrected for). The D3T treated mother showed a 1.6-fold increase in GST-activity
over the vehicle control mother. GST-activity levels, normalized by total cytosolic protein
concentration, are summarized in Figure 17.
Discussion Chapter IV
This chapter summarizes any and all inferences that could be drawn from the
experimental data reported in the previous section. For ease of discussion and lack of a viable
transition, this section has been divided into two parts. Part A addresses the steps leading up to
and involving AFB 1-DNA adduct studies, including the synthesis of 14C-AFB1 , the AFB 1-8,9-
epoxide, and AFB 1-DNA standards as well as the results of the kinetic studies on AFB 1-DNA
adduct formation and elimination. It will be the role of Part B, therefore, to address the
preliminary data gathered on the use of chemo-preventive agents to protect nursing pups from
subsequent AFB1 exposure.
Part A: Aflatoxin B1
Radio-labeled aflatoxin B1, specifically [3H]-AFB1, has been used previously, by our lab
and others, as a means to quantify AFB 1-DNA adduct formation in adult mouse and rat models.26
Attempting to quantify AFBI-DNA adduct levels in newborn mice, however, brought into
question the sensitivity of previous methods of detection due to the small physical size of the
animals and thus the small amount of total isolatable DNA. In an effort to address these issues of
sensitivity, a novel type of mass spectrometry-Accelerated Mass Spectrometry (AMS)-was to
be used, promising detection of the 14C-label on the sub-femtomole level (as low as
1 00atomoles).
Due to what seemed to be metabolic incorporation of the 14C-label into cellular
components of the treated mouse livers (i.e., nucleic acids and proteins), AFB 1-DNA adduct
measurements via AMS reported levels that were nearly five-fold higher than those of
preliminary studies using 3H-measurements. In an effort to circumvent these issues, AMS was
abandoned in favor of Stable-Isotope Mass Spectrometry (SIMS, aka Isotope Dilution Tandem
Mass Spectrometry28), which utilized synthesized internal standards to quantify levels of AFB1-
DNA adduction. While less sensitive than AMS, SIMS offered the opportunity to differentiate
between the various forms of AFB 1-DNA damage, specifically between the AFB1-N7-Gua and
AFB 1-FAPY adducts. Based on sensitivity analysis experiments, the limit of AFB 1-DNA adduct
detection (on the femtomole level) was more than sufficient to warrant the shift in methodology.
14C-Aflatoxin B1 Synthesis
While with previous studies 4C-AFB 1 was readily available by commercial purchase,
this study required synthesis of the compound due to a lack of present suppliers. For the
synthesis of 14C-AFB1 a biosynthetic approach, utilizing A. flavus, was preferred over a chemical
one due to both the complexity of the compound and literary precedent.29 30
Initial attempts to synthesize the compound were hindered by non-viable fungus and
possibly toxic trace metal contaminants in the purchased 14 C-acteate-sodium salt. In the end,
however, successful production of aflatoxin B1 was achieved and shown to rely on appropriate
growth conditions: an empirically optimized minimal growth medium, adequate aeration of the
suspension culture, precise temperature maintenance, and a longer incubation period than
described by others. Incorporation of 14C-label required introduction of 14C-acetate at least 72hr
after initial A. flavus inoculation; premature introduction of 14C resulted in incorporation of the
label into a variety of primary metabolites (i.e., proteins, nucleic acids, etc.) and not aflatoxin.
Allowing A. flavus to reach late exponential growth phase-when production of secondary
metabolites is more pronounced3 '-before inoculating the culture with 14C-acetate provided the
best theoretical chance for incorporation into AFB1 and the best empirical results. Ultimately,
despite the low synthetic yield, 14C-AFB1 was synthesized and purified in quantities large
enough for numerous future dosing events (>500).
Aflatoxin B-8,9-Epoxide Synthesis and Quantification
The AFB1 8,9-epoxide was synthesized on numerous occasions for subsequent use in the
synthesis of AFB1-('4N, "N)-DNA adduct standards and dose-response experiments with CHO-
AS52 cell-lines (performed by Roongtiwa Ann Wattanawaraporn). 'H-NMR spectra of the
parent AFB1 compound, the 8,9-epoxide, and the hydrolyzed AFBI-diol were clean with most, if
not all, chemical shifts able to be identified (see Figures 1, 2, and 3 and Tables 1 and 2). While
the AFB 1 spectrum was fairly easy to decipher, interpreting the spectra for the 8,9-epoxide and
the diol was more difficult due to the presence of numerous chemical species. In studying the 11H-
NMR spectrum for the AFB1-8,9-epoxide (Figure 2), it became clear that signature shifts, while
less intense than the exo-8,9-epoxide, were present for AFB1 and the endo-8,9-epoxide. Once all
the chemical shifts were identified and confirmed against available literature 24, integration
values for identifiable hydrogen chemical shifts were used to determine relative ratios of the
three species present in the reaction mixture. Hydrogen H9a (4.57ppm, d), H9a (4.28ppm, in), and
H8 (6.75ppm, t) were identified for their clean integration and unquestionable identity.
Surprisingly, key chemical shifts belonging to the AFB1-diol species (H6a: 6.6, H8 : 6.25, HO8 :
6.5, HO 9: 5.7, H9: 4.15, and H9a: 3.85ppm) were absent from the 8,9-epoxide spectrum, implying
next to zero hydrolysis of the formed 8,9-epoxide by the time the NNR was taken (approximately
lhr after synthesis). The AFBi-diol spectrum showed the loss of key exo- and endo-8,9-epoxide
chemical shifts (exo: H6a (6.27), H8 (5.67), H9 (3.99), and H9a (4.57); endo: H8 (5.82), H9 (4.13),
and H9a (4.28)) and appearance of signature diol peaks.
As previously mentioned, ready hydrolysis of the AFB 1-8,9-epoxide was slowed
drastically from its <10s half-life34, when the epoxidation reaction was carried out in a dried
solvent-system. Prolonged storage of the formed epoxide in anhydrous d6-DMSO proved
possible, when flash-frozen in a flame sealed ampule under argon. After three weeks of storage
at -80*C 90% of the formed exo-8,9-epoxide was still present.
Aflatoxin B-DNA Adduct Standard Synthesis
Stable-Isotope Mass Spectrometry (SIMS) utilizes stable-isotope analogs as internal
standards to quantify compounds of interest with femtomole sensitivity. In the case of
quantifying AFB 1-DNA adduct levels, AFB 1-15N-DNA analogs were synthesized via a combined
chemical-biosynthetic approach. Heavy nitrogen- 15 DNA was synthesized-utilizing an E. coli
biosynthesis-, isolated, and successfully reacted with epoxidized AFB1 providing relatively
large amounts of both the AFB 1-1 5N7-Gua and AFB 1-1 5N-FAPY standards (enough to perform
more than 5,000 measurements). Subsequent mass spectrometry analysis ensured that the
synthesis yielded high quality standards of exceptional purity.
AFB 1-14N-DNA adduct standards were synthesized as well and successfully used for
SIMS calibration purposes and standard curve generation (see Figure 4). Barring the noticeable
decrease in the signal-to-noise ratio, SIMS sensitivity analysis reported AFB1-14N-N7-Gua
detection as low as 1.5fmol. Such sensitivity was more than adequate for the AFB 1-DNA adduct
studies in newborn mice, which mandated detection of adduct quantities at least 100-fold greater.
Aflatoxin B-DNA Adduct Studies
This portion of my thesis was designed in light of a study performed by Vesselinovitch
and Wogan3 5 , which demonstrated near certain tumorigenesis (85-100%) in B6C3F1 mice
following a total administration of 6mg/kg AFB1 between days 4 and 7 following birth.
Understanding the long-term effects of dosing with 6mg/kg of AFB1 during this window of
extreme susceptibility, it was the joint goal of Dr. Leslie Woo and myself to explore the kinetics
of AFB 1-DNA adduct formation and removal in the B6C3F1 infant mouse-model. This baseline
analytical data on adduction patterns provides the first step in understanding the early signs of
cancer and will aid in interpretation of future data, which seek to uncover the biological
responses (i.e., transcriptional modulation and mutation) to specific patterns of adduction,
removal, and adduct persistence.
Consulting Figures 5 and 6, one sees that within hours of IP injection, AFB 1-N7-Gua
adducts in the livers of both males and females had already reached their peak (8.5 - 9.5
adducts/MB). Over the course of the next 48hr, any AFB 1-N7-Gua adducts that were not
hydrolyzed to the AFBI-FAPY adduct (or other more minor forms of DNA damage) were
effectively and near-completely removed from the mouse's liver. Preliminary AFBI-FAPY
adduct data showed AFB1-FAPY levels at their maximum 2hr after injection, suggesting a burst
of DNA adduction early on and an almost immediate conversion to the hydrolyzed product.
AFB1-FAPY adduct levels subsequently decrease at 4hr and then increase again at 8h, never
reaching levels higher than their AFB 1-N7-Gua precursor. From 8hr, AFB 1 -FAPY adduct levels
slowly decrease, at a rate of about one adduct/MB per day, to around 4 adducts/MB at 48hr.
These data agree fairly well with previous experiments conducted in rats, which showed AFB1-
N7-Gua adduct levels peak at 2hr and then decrease rapidly, while AFB 1-FAPY adduct levels
increased to a maximum and then persisted well past the 72hr test window.37 While in vitro
repair mechanisms have been demonstrated for the AFB1-FAPY adduct, in situ evidence for
mechanisms of AFB1-FAPY removal has yet to be shown. Persistent burden of the AFB1-FAPY
adduct is believed to be a major source of downstream mutation and carcinogenicity. 38
While age was clearly an important factor to the outcome of the original study, so too
was gender. Females treated in the original study with the same AFB1 regimen demonstrated
incredibly low tumor incidence, less than 7.1% in all cases. An additional goal of this work was,
therefore, to try to determine if the lower sensitivity of the females could be due to a lower yield
of DNA adducts. Although AFB 1-N7-Gua adduct levels in female neonates showed a slight
reduction when compared to their male counterparts, a statistically significant difference was not
observed. This finding was somewhat expected, as rigorous gender differences in mice do not
seem to take hold until the third-week of life, following weaning. It will still be interesting,
however, to see if the AFBi-FAPY adduct results show significant gender differences.
Part B: Chemo-Preventive Intervention
The objective of this segment of my thesis was to gather preliminary data on the effects
of chemo-preventive agents on neonates, earlier in life. In an effort to extend the relevance of our
work to a more relatable system, experiments were performed in which the source of neonatal
exposure to various chemical agents (i.e., sulforaphane, D3T, and AFB1) was limited to the
mother, by way of her milk. Up to this point no known literature has been published utilizing
such a maternal-neonatal mouse system.
Select sulfur containing-compounds, such as sulforaphane and D3T, have been shown to
be potent inducers of Phase II ezymes, through activation of Nrf2-mediated gene
transcription. 23,34 Low micromolar concentrations of sulforphane and even lower concentrations
of D3T have been shown to elevate expression levels of detoxification enzymes across multiple
species, while significantly reducing those of CYP enzymes in certain species, namely humans
(little to no reduction of CYP enzymes have been reported in rodents).25 While the effects of
such chemo-preventive agents have been assessed at later ages in animal life, no studies have
been conducted investigating the effects of such chemo-preventive compounds in nursing
mothers and their infants.
Sulforaphane
Previous experimentation has shown that infant mice being nursed by an AFB1-treated
C57BL/6J mother form AFB 1-DNA liver adducts of their own, suggesting AFB 1 exposure
through milk to be possible. Preliminary chemo-preventive studies on the levels of AFB 1-DNA
adduct formation in nursing pups following sulforaphane pre-treatment (2mg per day for three
consecutive days) and subsequent AFB1 treatment (12mg/kg) of C57BL/6J nursing mothers,
however, showed no significant changes. This finding prompted some important questions: (1) is
sulforaphane transferable to nursing pups in an "effective" form? (2) Does sulforaphane have the
same effect on neonates that it does on adult mice? And (3) is enough sulforaphane being
administered to the nursing mothers to see an effect in their feeding pups? To address these
questions a two-pronged preliminary study was performed utilizing a Glutathione S-Transferase
(GST) protein-activity assay in conjunction with real-time RT-PCR to monitor the upstream
transcription levels of key proteins, elemental to AFB1 metabolism, as a function of treatment
with select chemo-preventive agents.
Real-time RT-PCR data for those pups nursed by a 2mg sulforaphane-treated mom
suggested a statistically significant (p < 0.05) increase in mRNA levels of two genes over the
control group. A positive induction of gene transcription levels was observed for both
Cytochrome P450 2a4/5 (1.6-fold induction) and epoxide hydrolase 1 (three-fold induction) by
day three of nursing. Assuming that these results are not simply artifacts of differential gene
expression at an aggressive (possibly unpredictable) developmental stage in life, these data
suggest that sulforaphane is indeed transferrable from treated-mothers to nursing pups and in
sufficient enough quantities to affect change on the level of mRNA transcription.
As one would thus expect, infant pups nursed by a 5mg sulforaphane-treated mom
showed an even greater effect in even more genes. Data for Cytochrome P450s la2 and 2b9
suggested a statistically significant 1.5-fold reduction in transcript levels and a near three-fold
elevation in mRNA levels for the glutamate-cysteine ligase catalytic subunit (not examined in
2mg-treated pups), which is responsible for the last rate-limiting step in glutathione synthesis.
Oddly, however, these pups showed an approximate 1.5x statistical reduction in the mRNA
levels of Cytochrome P450 2a4/5-the same gene that saw an induction in pups being nursed by
the 2mg sulforaphane-treated mouse.
In an effort to explain this observed contradiction, RT-PCR data obtained for individual
pups was examined. On studying the absolute values of the relative transcript concentrations in
Figures 8,9,11 and 12, one observes an intriguing difference between the 2mg and the 5mg
sulforaphane-treatment/control groups: across the board, gene transcript levels for the 2mg
treatment/control groups are lower than the those for the 5mg group. Relative transcript levels
between respective genes of the two control groups show a five-fold increase (from the 2mg-
control to the 5mg-control) on average and in the extreme case of Cyp2a4/5 a 72-fold change.
This overall increase in relative concentrations from the 2mg to the 5mg control group, while
lessened between treatment groups, was still observed with an average three fold-difference in
"non-induced" genes. While less can be stated about differences between treatment groups, due
to obvious differences in said treatments, this observation as a whole was troubling and
potentially suggested fault in one if not both experiments. Consulting relative gene transcript
levels for the D3T-contol group, however, one sees basal levels more consistent with the 5mg
sulforaphane treated group.
It should be mentioned that while there are ways to mitigate this sort of variation, or
potential error, by performing biological and technical replicates (at least in triplicate),
conducting a study of this sort is fairly tricky, due to the presence of several foreseeable, yet
uncontrollable variables. From an animal behavioral point of view, intra-litter differences could
arise from varied feeding patterns of pups, while vast inter-litter variations could arise from
differences in a mother mouse's ability to care for her young properly/effectively.
In neither the 2mg nor the 5mg sulforaphane treatment groups was there a significant
change in the nursing pup's levels of Gsta2 or Gsta3. While the 2mg treatment group observed a
greater than three-fold increase in Ephx1 relative mRNA levels, potentially implying a protective
induction, no such increase was seen in the 5mg treatment group.
The Glutathione S-Transferase (GST)-activity assay has been used previously by Pat
Egner (of the Groopman Lab), and others as a gross-indicator of GST levels, and thus induction
of Phase II protective enzymes. Preliminary GST-activity assay results for pups of the 5mg
sulforaphane treatment/control set did not show significant differences; both the control and
sulforaphane-exposed pup in fact had identical normalized GST-activity levels of 213
mmol/min/mg protein.
These data, taken in stride with the results found in the RT-PCR and DNA adduct studies,
suggested that while sulforaphane is apparently transferrable via milk from nursing C57BL/6J
mothers to their pups, due to either the amounts of sulforaphane transferred, sulforaphane's
transferred form (potentially metabolized), or sulforaphane's inability to effect neonates, chemo-
preventive treatment of mothers did not hugely alter the metabolic state of her pups following a
three-consecutive day treatment regimen.
3H-1,2-dithiole-3-thione
While sulforaphane, when used to treat nursing mothers, seemed to have a downstream
effect on the gene transcript levels of her feeding pups, the response was not a robust one.
Assuming that this lackluster induction was ultimately due to the effective dose of sulforaphane
that reached the nursing infants, D3T-a more potent chemo-preventive Nrf2-inducing
compound-was tested for its potentially greater effects.
C57BL/6J nursing mothers (obtained as time-pregnant females from Jackson Labs) were
treated with 300ptmol/kg D3T via gavage for three consecutive days, starting day four post
partum. Similar to those studies with sulforaphane, pups (and mothers in this case) were killed
and their livers collected eight hours after the final dose. RT-PCR and GST-activity assays were
successfully performed on each of the livers collected.
Real-time RT-PCR data for day-six pups nursed by a D3T-treated mother showed no
statistically significant changes (p < 0.05) in the nine monitored genes, on average, over pups of
the control group. While a slight elevation in mRNA levels of Gsta3 (1.5x) and Gele (2.5x) was
observed they were not deemed significant by the Student T-Test with p-values of only 0.062
and 0.055, respectively. These data suggest that, while these nursing infants were feeding
(judged by weight increase), D3T-regardless of its potency-was either not transferred
effectively through the mother's milk, was transferred but in an unusable metabolized form, or
simply incapable of inducing the same sort of effects seen in adult mice, in infants of that age.
While nursing pups exposed to D3T, by way of their mother's milk, were not privy to
much of its effect, RT-PCR data from the 300ptmol/kg D3T treated-nursing mother showed large
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effects in interrogated genes, over the control mother. Six out of the nine monitored mRNA
transcipts (Cyp's 1a2, 2a4/5, Gsta2, Gclc, Ephxl, and Nqol) experienced an approximately five-
fold or greater induction in the D3T-treated nursing mother than in the control mom. Consistent
with the D3T's Phase II induction properties, Gsta2 experienced a 17-fold increase, while Gclc,
Ephxl, and Nqol saw a 17.3, 4.7 and 5.8-fold induction, respectively, in the D3T treated mom
over the control mom. In line with sulforaphane's deviant effect on rodents 39, in comparison to
humans, D3T's effect on three of the four Cyp's tested was that of an inductive one (rather than a
reductive one): bolstering Cypla2, Cyp2a4/5, and Cyp2b9's mRNA levels to more than five,
11.5, and 1.5-fold that of the control's. Outside of being informative, these resonating results
serve as a positive control, indicating successful introduction of the compound into the nursing
mother's system.
GST-activity assay results for 15 pups in total (seven control and eight D3T-exposed) did
not show an increase in GST activity (as predicted based on RT-PCR results). The average
control GST-activity for nursing pups was 382 mmol/min/mg protein, while the average activity
for D3T-exposed pups was 379 mmol/min/mg protein. GST-activity assay results for the control
and D3T-treated moms showed a 1.6x increase in total GST activity, from 591 (control mom) to
946 mmol/min/mg protein (D3T-treated mom)-a result consistent with previous literature. 41 An
additional point of interest was found in comparing the background levels of GST-activity for the
infant controls to that of the adult control mouse: an approximate 1.5-fold increase with age. This
gross-increase in the basal GST-activity as a function of age correlates well with this strain's
known transition from being susceptible to AFB1 's carcinogenic effects to completely refractory.
Both the RT-PCR and the GST-activity assay results strongly suggest that while D3T is
capable of inducing a robust response in the treated mothers, a similar effect in nursing pups is
absent. This lack of a response could again be due either to D3T's inability to be transferred
through the mother's milk, the fact that it is metabolized into an unusable form by the nursing
mothers and then transferred, or simply is not capable of inducing the same effect on infant pups
that early in life, that it does on adult mice.
As stated prior, the goal of this thesis was to present a more extensive look on the
inductive effects of D3T transmission to nursing pups. Due to what seemed to be toxic, and
occasionally lethal, effects of D3T overdose after a single dose in multiple nursing females,
however, a large number of samples were not collected. This unforeseen D3T toxicity seemed a
bit bizarre for the attempted dosing regimen, based on previous publications and the initial D3T
experiment performed (discussed earlier). While toxic effects of other chemo-preventive Phase II
enzyme-inducing agents, such as Oltipraz (a D3T derivative), have been acknowledged for some
time, 300ptmol/kg D3T dosing regimens have been used prior with no reported signs of
toxicity." Previous experiments conducted in non-nursing mice (performed by collaborator Pat
Egner) saw signs of gastrointestinal distress at D3T doses of 500ptmol/kg, but never mouse
death. To rule out potential toxic impurities from D3T's synthesis, the same stock of D3T was
used to treat non-nursing C57BL/6J females and zero signs of toxicity were observed. Since the
control mice were always in good health, before and after the three-day regimen, poor gavage
technique or toxicities due to the vehicle used were also ruled out. These unsuccessful attempts
to identify the precise source of this reproducible toxicity/lethality point a strong finger at the
animals being used. Mice used for these D3T experiments (including the presented earlier) were
all purchased as time-pregnant females from the same supplier, Jackson Labs, albeit were
received several weeks apart. Therefore my hypotheses are as follows: (1) something was
different with the latter batches of time-pregnant mice received (either genetically or maybe
through development of an allergy) or (2) post-partum nursing mothers, due to severe hormonal
fluctuations are increasingly sensitive to D3T and possibly other potent Phase II enzyme
inducing compounds (and the preliminary mouse that survived was simply a lucky gal).
Conclusion and Future Directions
Conclusion
This thesis had three coherent objectives: (1) Synthesis of 14C-aflatoxin B1 and AFB1-
1N-DNA standards to aid in detection and analysis of in vivo generated AFB 1-DNA adducts; (2)
Kinetics analysis of AFB1-N7-Gua and AFB1-FAPY adduct formation and elimination in the
B6C3F1 mouse-model; and (3) A preliminary analysis on the downstream effects in pups of
treating nursing C57BL/6J mothers with chemo-preventive agents, sulforaphane and D3T.
'
4C-AFB1 was successfully synthesized utilizing a biosynthetic approach. Although a low
synthetic incorporation was ultimately obtained (< 1% of total 14C-label introduced), sufficient
quantities of 14C-AFB1 were procured to conduct several future experiments. Both AFB1-
('4N,"N)-DNA internal standards were successfully synthesized in good yield utilizing a
combined biochemical approach, HPLC purification, and UV/Vis spectrophotometric
quantification.
More than 75 neonates were successfully dosed with 6mg/kg AFB1, their liver DNA
isolated, and partially analyzed via SIMS for AFB1-N7-Gua and AFB1-FAPY adduct levels at six
time-points (2, 4, 8, 12, 24, and 48hr) post-dosing. The kinetics of AFB1-N7-Gua formation
showed a maximum adduct level at 2hr (8.9 adducts/MB) followed by a sharp removal of
adducts after the 4hr time-point. Preliminary AFB1-FAPY adduct studies depicted a bimodal
kinetic curve with global and local peak at 2 (5.9 adducts/MB) and 8hr (5.7 adducts/MB) post-
dose, respectively, followed by a gradual decline in adduct levels, averaging 4 adducts/MB 48hr
post-dose. Although slightly hopeful, no significant gender differences were observed for AFB 1-
N7-Gua adduct levels; AFBi-FAPY results are still pending.
Preliminary chemo-preventive RT-PCR and GST-activity assay results suggest that while
sulforaphane is readily transferred via breast milk, D3T is either not transferred, transferred as an
ineffective metabolite, or incapable of inducing an effect in six-day old neonates. This deduction
further implies that by prescribing nursing mouse mothers (and perhaps by extension nursing
humans mothers) either sulforaphane or D3T, one could expect different downstream effects on
the nursing infant(s), regardless of the similarity of their molecular target.
A statistically significant (p < 0.05) elevation in mRNA levels for Gclc (2.88) was
observed, while similar reductions in gene transcript levels for Cypla2 (-1.54), Cyp2a4/5 (-1.48),
and Cyp2b9 (-1.51) were noted for pups nursing from a 5mg R,S-sulforaphane treated mother.
Be that as it may, transferred sulforaphane does not seem capable of producing a robust enough
response in nursing infant mice to provide protection from AFB 1-DNA adduct formation.
Future Directions
These experiments have laid the foundation for work to come. Part of a larger objective
to calibrate the B6C3F1 gpt-delta mouse as a model for human disease, these AFB 1-DNA adduct
studies provide a key set of information on a timeframe elemental in AFB1 induced
carcinogenesis. The next steps include completing SIMS kinetics analysis for AFB 1-N7-Gua and
AFB1-FAPY adduct formation and removal in neonatal liver samples collected following a
stepwise exposure model (3 doses of 2mg/kg AFB1 given days 4, 7, and 10 after birth) in
addition to those remaining from experiments of the single 6mg/kg bolus injection. It will be
interesting to see how the kinetics of adduct formation and removal differ between the two
different types of exposure-multi-dose versus single bolus injections-especially in the levels
of the AFB 1 -FAPY adduct.
Following completion of the kinetics studies, mutational analysis studies should be
performed for both the chronic (multi-dose) and acute exposure scenarios. Using the gpt-delta
mouse model it will be interesting to see the sorts of gender stratified mutational events (point
mutations versus deletions) that occur as a function of AFB1 exposure. These subsequent
experiments will provide key information, which will allow us to further correlate the nature of
adduct formation and the persistence of adducts with AFB1 's mutational spectrum. Such
correlations will provide the framework for relating kinetic, qualitative, and quantitative patterns
of DNA damage and mutation to age and gender.
On the downstream effects of chemoprevention in nursing mothers, additional
experiments need to be performed before accepting those conclusions made on the basis of
preliminary studies. First and foremost, a dose-response curve needs to be generated for both
sulforaphane and D3T in C57BL/6J nursing mothers (four days post-partum), in order to
determine appropriate dosing regimens, free of toxic or lethal side effects. Once complete, a
more robust dataset including at least six litters (three control and three treatment) for each
chemo-preventive agent should be generated using the same RT-PCR and enzyme-activity
approaches. A more sensitive enzyme-activity assay, such as the qinone-reductase (QR) assay,
could be used in place of the potentially less descriptive GST-activity assay. Additional methods
could be enlisted to directly assay sulforaphane metabolite levels in the blood and urine of
nursing pups or even the milk of nursing mothers. Those sorts of experiments could offer a
definitive answer to the question of whether or not sulforaphane was being successfully
transferred to the pups.
It is known that a major AFB1 metabolite found in the breast milk of several species,
AFM 1, has carcinogenic effects only slightly lower than AFB1 itself.' Thus it will be necessary to
also synthesize AFM1-15N-DNA adduct standards in order to identify and correctly quantify total
DNA adduct burden in the nursing pups.
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Diagram 1. Aflatoxin B1 metabolism
This diagram provides a overview of AFB1 metabolism from the parent compound to DNA adduct. Cytochrome P450s
are responsible for the Phase I metabolism of AFB1 to the corresponding exo-8,9-eopxide, AFM 1, and AFQi metabolites.
Subsequent Phase II metabolism by Glutathione S-Transferases (GSTs) and Epoxide Hydrolases (EPHX) produces the
AFB 1-glutathion conjugate and the AFB 1-dyhydrodiol deactivated products. In place of Phase II metabolism the AFB 1
exo-8,9-epoxide is capable of reacting with the N7-position of pyrimmidines (most commonly Guanine) to form the





Proton Shift S littin Shift S littin
Hi + DMSO 2.50 m
-H2+ H20 3.31 m
H4 (OMe) 3.94 s
IH5 6.78 S
H6a 6.96 d 6.62 d
H8  6.75 t 5.27 s
H9  5.41 t 4.17 s
H 9 a 4.80 m 3.87 d
Acetone 2.08 s
DCM 5.73 s
Table 1. AFB1 and AFB1-8,9-diol H-NMR table
This table provides chemical shift values and splitting patterns for
peaks present in 'H-NMR spectra obtained for solutions containing
AFB1 and the AFB1-diol (Figures 1 and 3, respectively). The
hydrogen numbering system coincides with that used to number
AFBi in Diagram 1.
AFBExo-AFB-8,9-Eoxide Endo-AFB-8,9-Eoxide
Proton Shift Splittin Inte ration Shift Splittin Integrat Shift Slittin Integration
H1 +DMSO 2.50 mm
H2 + H20 3.31 ms
H4 (OMe) 3.94 ss
H5  6.78 s 0.0374 6.80 s 1.0257 6.68 s 0.1025
H 6 a 6.96 d 0.0537 6.27 d 1.0000 6.97 d
H8  6.75 t 0.0496 5.66 dd 0.9789 5.82 d 0.1091
H9 5.41 t 0.0536 3.99 d 1.0461 4.13 m 0.1764
H9 a 4.80 4-57 1.0257 4.28 0.1458
Acetone 2.08 s
Table 2. AFB-8,9-epoxide reaction mixture H-NMR table
This table provides chemical shift values, splitting patterns, and integration values for peaks detected in the H-NMR spectrum obtained for the AFBi-
8,9-epoxide reaction mixture (Figure 2). The hydrogen numbering system coincides with that used to number AFB1 in Diagram 1.
2mg R,S-Sulforaphane I 5mg R,S-Sulforaphane 1 300pmol/kg D3T _
Treated Fold-Change P-value Control Treated
Fold-
Change P-value Control Treated
Fold-
Change P-value
Cyp1a2 0.85 0.56 -1.53 0.067 1.93 1.25 -1.54 0.011 1.77 2.00 1.13 0.138
Cyp2a4/5 0.01 0.02 1.64 0.005 0.73 0.50 -1.48 0.011 0.59 0.56 -1.06 0.187
Cyp3all 0.22 0.33 1.51 0.076 1.72 1.29 -1.32 0.091 1.74 1.38 -1.26 0.491
Cyp2b9 0.60 0.64 1.07 0.388 3.20 2.12 -1.51 0.016 2.82 3.04 1.08 0.156
Gsta2 0.93 0.62 -1.50 0.087 1.15 1.23 1.06 0.338 1.98 1.80 -1.10 0.199
Gsta3 0.42 0.37 -1.14 0.283 2.32 1.98 -1.17 0.131 1.26 1.90 1.51 0.062
Gclc 0.56 1.62 2.88 0.000 0.55 1.35 2.46 0.055
Ehxl 0.32 1.01 3.12 0.020 1.09 1.18 1.08 0.320 1.38 1.17 -1.18 0.231
NMo 0.36 0.37 1.03 0.419 0.38 0.28 -1.35 0.245
Aip 1.21 0.76 -1.60 0.050 1.15 1.15 1.01 0.442 1.16 1.14 -1.02 0.465
Cxxcl 1.00 1.20 1.20 0.050 0.85 0.85 -1.01 0.442 0.84 0.86 1.02 0.388
Table 3. RT-PCR results
This table provides real-time RT-PCR results for mRNA obtained from pups
C57BL/6J mothers. Normalized (by the average of two housekeeping genes:
nursing from 2mg and
Aip and Cxxc I) group
columns. The ratio (Treated/Control) of these relative averages are reported in the columns entitled
5mg R,S-sulforaphane and 300pmol/kg D3T-treated
averages are reported in the "Control" and "Treated"
"Fold-Change" and p-values, assessing statistical
significance (determined by the Student T-Test) of these fold-changes are reported in the adjacent columns. Yellow highlighted regions represent genes within
a specific control/treatment group which showed a statistically significant (p < 0.05) elevation or reduction in detected mRNA levels.
Control
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Figure 1. AFBI 1H-NMR spectrum
The spectrum above was obtained on a BrUker 400 NMR instrument (32 scans) by dissolving approximately 1mg AFB1
in 700jL anhydrous d,-DMSO. Chemical shift values and splitting patterns are further analyzed in Table 1.
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Figure 2. AFB1-8,9-epoxide reaction mixture 'H-NMR spectrum
The spectrum above was obtained on a Braker 400 NMR instrument (32 scans) by dissolving approximately 3mg total
of AFB1, the AFB1-8,9-epoxide, and AFB 1-diol (21:3:1, representing the ratio of integration values for protons H 9a, H9a,
and H8, respectively) in 700pL anhydrous d6-DMSO. Chemical shift values, splitting patterns, and integration values are
reported in Table 2.
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Figure 3. AFB1-8,9-diol 'H-NMR spectrum
The spectrum above was obtained on a Brnker 400 NMR instrument (32 scans) by adding a few drops of
H20 to an NMR-tube containing the AFB 1-8,9-epoxide in 700ptL anhydrous d,-DMSO. Upon analysis
signature chemical shift patterns for both AFB1 and the AFB 1-8,9-diol were detected in the above
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Figure 4. SIMS AFBi-N7-Guanine standard curve
To determine SIMS limit of detection and generate a standard dilution curve, six geometric dilutions of AFBi-N7-Guanine (50, 25,
12.5, 6.25, 3.125, and 1.5625finol) were measured against a constant amount of AFB1-'5N7-Guanine internal standard. Results are
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Figure 5. SIMS AFB1-N7-Guanine 48hr kinetics results
This figure depicts a kinetic time-course for AFB1-N7-Guanine adduct formation and removal in four-day old pups following 6mg/kg
AFB1 IP injections in 1pOgL DMSO. Six time-points were assessed in total (2, 4, 8, 12, 24, and 48hr post-dosing) and plotted as gender
separated and combined sets (see legend at top of figure). Whole-liver DNA isolations were performed (by Leslie Woo) and adduct
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Figure 6. SIMS AFB1-FAPY 48hr kinetics preliminary results
This figure depicts a kinetic time-course for AFB1-FAPY adduct formation and removal in four-day old pups following 6mg/kg AFB1 IP
injections in 1 0ptL DMSO. These data points represent preliminary results for dosing and killing two pups per time-point at 2, 4, 8, 24,
and 48hr post-dosing. Whole-liver DNA isolations were performed (by Leslie Woo) and adduct levels measured by Pat Egner, via






Control 2mg Sulforaphane Fold e
0 -1.00
-2.00
i Cypla2 .. Cyp2a4/5 a Cyp3all * Cyp2b9 a Gsta2 a Gsta3 Ephx1 a Aip Cxxcl
Figure 7. Averaged RT-PCR results for pups nursed by 2mg R,S-sulforaphane and vehicle-control treated moms
This figure depicts average mRNA levels (obtained via one-step real-time RT-PCR) and fold-change differences between pups nursed
by mothers treated with 2mg R,S-sulforaphane and a corn-oil vehicle-control for days four, five, and six post-partum. Eight hours after
the final dose, eight pups in total (four control and four sulforaphane-nursed) were killed, their livers collected, and stored at -80*C.
One-step real-time RT-PCR was conducted and mRNA levels for nine genes (see legend at base of figure) were reported as relative
amounts, normalized by the average of two housekeeping genes (Aip and Cxxc 1). The Fold-Change is reported as either a positive or
negative ratio corresponding to either an elevation or reduction in mRNA levels, respectively, following chemo-preventive treatment of
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Figure 8. RT-PCR results for individual pups nursed by a (2mg R,S-sulforaphane) vehicle-control-treated mom
This figure depicts individual mRNA levels (obtained via one-step real-time RT-PCR) for pups nursed by a mother treated with 200pL
corn-oil vehicle-control for days four, five, and six post-partum. Eight hours after the final dose, four pups were killed, their livers
collected, and stored at -80*C. One-step real-time RT-PCR was conducted and mRNA levels were reported for nine genes in total (see
legend at base of the figure) as relative amounts, normalized by the average of two housekeeping genes (Aip and Cxxcl). These
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Figure 9. RT-PCR results for individual pups nursed by a 2mg R,S-sulforaphane-treated mom
This figure depicts individual mRNA levels (obtained via one-step real-time RT-PCR) for pups nursed by a mother treated with 2mg
R,S-sulforaphane in 200ptL corn-oil for days four, five, and six post-partum. Eight hours after the final dose, four pups were killed,
their livers collected, and stored at -80*C. One-step real-time RT-PCR was conducted and mRNA levels were reported for nine genes in





-M Control 5mg Sulforaphane d- ange
-1.00 -
-2.00
w Cypla2 Cyp2a4/5 & Cyp3all * Cyp2b9 m Gsta2 a Gsta3 Gclc - Ephx1 Nqol 1 Aip Cxxc1
Figure 10. Averaged RT-PCR results for pups nursed by 5mg RS-sulforaphane and vehicle-control treated moms
This figure depicts average mRNA levels (obtained via one-step real-time RT-PCR) and fold-change differences between pups nursed by
mothers treated with 5mg R,S-sulforaphane and a corn-oil vehicle-control for days four, five, and six post-partum. Eight hours after the
final dose, 11 pups in total (five control and six sulforaphane-nursed) were killed, their livers collected, and stored at -80*C. One-step
real-time RT-PCR was conducted and mRNA levels for 11 genes (see legend at base of figure) were reported as relative amounts,
normalized by the average of two housekeeping genes (Aip and Cxxc 1). The Fold-Change is reported as either a positive or negative
ratio corresponding to either an elevation or reduction in mRNA levels, respectively, following chemo-preventive treatment of the
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Figure 11. RT-PCR results for individual pups nursed by a (5mg R,S-sulforaphane) vehicle-control-treated mom
This figure depicts individual mRNA levels (obtained via one-step real-time RT-PCR) for pups nursed by a mother treated with 200tL
corn-oil vehicle-control for days four, five, and six post-partum. Eight hours after the final dose, five pups were killed, their livers
collected, and stored at -80*C. One-step real-time RT-PCR was conducted and mRNA levels were reported for 11 genes in total (see
legend at base of the figure) as relative amounts, normalized by the average of two housekeeping genes (Aip and Cxxc1). These
experiments were performed and prepared in parallel with the 5mg R,S-sulforaphane experiments (Figure 12).
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Figure 12. RT-PCR results for individual pups nursed by a 5mg RS-sulforaphane-treated mom
This figure depicts individual mRNA levels (obtained via one-step real-time RT-PCR) for pups nursed by a mother treated with 5mg
R,S-sulforaphane in 200tL corn-oil for days four, five, and six post-partum. Eight hours after the final dose, six pups were killed, their
livers collected, and stored at -80*C. One-step real-time RT-PCR was conducted and mRNA levels were reported for 11 genes in total
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Figure 13. Averaged RT-PCR results for pups nursed by D3T and vehicle-control-treated moms
This figure depicts average mRNA levels (obtained via one-step real-time RT-PCR) and fold-change differences between pups nursed
by mothers treated with 300pmol/kg D3T and a DMSO:Cremaphor:DPBS vehicle-control for days four, five, and six post-partum. Eight
hours after the final dose, nine pups in total (four control and five D3T-nursed) were killed, their livers collected, and stored at -800C.
One-step real-time RT-PCR was conducted and mRNA levels for 11 genes (see legend at base of figure) were reported as relative
amounts, normalized by the average of two housekeeping genes (Aip and Cxxc 1). The Fold-Change is reported as either a positive or
negative ratio corresponding to either an elevation or reduction in mRNA levels, respectively, following chemo-preventive treatment of
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Figure 14. RT-PCR results for individual pups nursed by a (D3T) vehicle-control-treated mom
This figure depicts individual mRNA levels (obtained via one-step real-time RT-PCR) for pups nursed by a mother treated with
DMSO:Creamaphor:DPBS vehicle-control for days four, five, and six post-partum. Eight hours after the final dose, five pups were
killed, their livers collected, and stored at -80*C. One-step real-time RT-PCR was conducted and mRNA levels were reported for 11
genes in total (see legend at base of the figure) as relative amounts, normalized by the average of two housekeeping genes (Aip and
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Figure 15. RT-PCR results for individual pups nursed by a D3T-treated mom
This figure depicts individual mRNA levels (obtained via one-step real-time RT-PCR) for pups nursed by a mother treated with
300pmol/kg D3T in DMSO:Creamaphor:DPBS for days four, five, and six post-partum. Eight hours after the final dose, four pups
were killed, their livers collected, and stored at -80*C. One-step real-time RT-PCR was conducted and mRNA levels were reported for
11 genes in total (see legend at base of the figure) as relative amounts, normalized by the average of two housekeeping genes (Aip and
Cxxc 1). Individual pup size and gender are reported as well.
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Figure 16. RT-PCR results for D3T vehicle-control and treated moms
This figure depicts mRNA levels (obtained via one-step real-time RT-PCR) and fold-change differences between two mothers treated
with 300 mol/kg D3T and a DMSO:Cremaphor:DPBS vehicle-control for days four, five, and six post-partum. Eight hours after the final
dose, both moms were killed, their livers collected, and stored at -80*C. One-step real-time RT-PCR was conducted and mRNA levels for
11 genes in total (see legend at base of figure) were reported as relative amounts, normalized by the average of two housekeeping genes
(Aip and Cxxc 1). The Fold-Change is reported as the either a positive or negative ratio corresponding to either an elevation or reduction
in mRNA levels, respectively, following chemo-preventive treatment.
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Figure 17. Averaged GST-activity assay results
This figure depicts average GST-activity levels for pups nursed by mothers treated with 300pmol/kg D3T, 5-mg R,S-sulforaphane or
vehicle-control for days four, five, and six post-partum. GST-activity levels are also reported for the respective D3T and (D3T) vehicle
control-treated mothers. Eight hours after the final dose, 17 pups (seven D3T, eight (D3T) vehicle-control, one 5mg R,S-sulforaphane,
and one corn-oil vehicle-control nursed) and two moms (one D3T and one vehicle-control-treated) were killed, their livers collected,
and stored at -80*C. 20-30mg liver aliquots were homogenized, centrifuged at 105,000xg for one hour at 4*C, and their cytosolic
fractions assayed for GST-activity, using a GST-activity kit (purchased from Sigma Aldrich). For each set, the blue (left) column
represents treated mice while the red (right) column represents control mice. While both the D3T and 5mg R,S-sulforaphane nursed
pups failed to show much of a difference, on average, the D3T-treated mom showed a 1.6-fold elevation in GST-activity over the
(D3T) vehicle-control mom. 78
